Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardura Advisory Cmte. To Discuss Limiting Hypertension Use To Second-Line

Executive Summary

FDA's Cardiovascular & Renal Drugs Advisory Committee is expected to discuss limiting Pfizer's Cardura (doxazosin) to second-line treatment for hypertension May 24.

You may also be interested in...



Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.

Any potential changes to Pfizer's antihypertensive therapy Cardura (doxazosin) labeling should await additional data from NIH's ALLHAT study, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 24.

Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.

Any potential changes to Pfizer's antihypertensive therapy Cardura (doxazosin) labeling should await additional data from NIH's ALLHAT study, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 24.

Scios Natrecor

Cardiovascular & Renal Drugs Advisory Committee will discuss nesiritide for treatment of acute congestive heart failure May 25. Scios will present data from the 498-patient Vasodilation in the Management of Acute Congestive heart failure trial begun in October 1999. FDA found the agent "non-approvable" and requested further study in April 1999. Scios submitted the amended NDA Jan. 10. The meeting will be held at the National Institutes of Health Masur Auditorium in Bethesda, Md. beginning at 9 a.m. The committee will review Pfizer's Cardura (doxazosin) May 24 beginning at 8:30 a.m. (1"The Pink Sheet" April 9, p. 31)

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel